摘要
目的探讨紫杉醇(paclitaxel)联合氟尿嘧啶(5-Fu)及顺铂(CDDP)的治疗方案(简称PFC方案)对进展期胃癌患者外周血淋巴细胞表型的影响.方法 47例经病理学或细胞学确诊的进展期胃癌患者,采用PFC方案化疗(紫杉醇50 mg/m2,静滴3 h, 第1,8,15天;5-Fu 750 mg/m2,用便携式微量输液泵持续静脉输注,第1～5天;CDDP 20 mg/m2,静滴,第1～5天;每4周重复).应用流式细胞仪检测CD3+、CD4+、CD8+、CD16+ 56+、CD19+细胞的百分率.结果进展期胃癌患者经PFC方案化疗后CD4+、CD4+/CD8+、CD16+56+较化疗前显著升高(P＜0.05);CD3+、CD8+、CD19+化疗前后差异无显著性(P＞0.05).结论 PFC方案化疗可改善进展期胃癌患者机体的免疫功能.
Objective To evaluate the changes in peripheral lymphocyte subsets by flow eytometry of PFC regimen in the treatment of 47 patients with advanced gastric cancer. Methods A total of forty-seven patients with a pathologic enrolled in the study. The patients were treated with paelitaxel 50 mg/m^2 infusion for 3 h or day 1,8,15;on day 1 to 5 infused with 5-Fu 750 mg/m^2 using an ambulatory pump;and eisplatin 20 mg/m^2 infusion on day 1 to 5 administrated in 28 day cycle. Every patient must be treated for two cycles then evaluated with the flow eytometry for T lymphocyte subsets, NK cell and CD19^＋. Results The expressive rates of CD4^＋ , CD16 ＋ 56^＋ and the ratio of CD4^＋/CD8^＋ in peripherorl blood were higher in post-treatment patients than in pre-treatment samples （P 〈 0.05）. No evident case of changes of CD3^＋ , CD8^＋ , CD19^＋ positive cell percentage were observed after chemotherapy （P 〉 0.05 ）. Conclusion PFC regimen for advanced gastric cancer can activate patients immune function.
出处
《中国肿瘤临床与康复》
2005年第6期481-483,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
